Camille E Horrocks, | |
100 N Eaglewood Dr, North Salt Lake, UT 84054-3014 | |
(801) 589-4862 | |
Not Available |
Full Name | Camille E Horrocks |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 100 N Eaglewood Dr, North Salt Lake, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1588327977 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Camille E Horrocks, 100 N Eaglewood Dr, North Salt Lake, UT 84054-3014 Ph: (801) 589-4862 | Camille E Horrocks, 100 N Eaglewood Dr, North Salt Lake, UT 84054-3014 Ph: (801) 589-4862 |
News Archive
In the United States, African Americans have approximately twice the risk of end-stage renal disease compared to white Americans, despite a similar prevalence in earlier stages of chronic kidney disease. A large study co-authored by George Washington University researcher Dominic Raj, M.D., identifies factors that mediate differences in the progression of chronic kidney disease between black patients and white patients, as well as among black patients, in order to reduce the excess burden of end-stage renal disease and its complications in black patients.
The National Cancer Research Institute, Cancer Research UK and Public Health England's National Disease Registration Service hosted a Cancer/Covid-19 Research Summit with researchers from different disciplines discussing the impact that Covid-19 is having on cancer services and research.
A new study adds to the data on the optimum interval between the first and second doses of the adenovirus vectored COVID-19 vaccine.
Arrowhead Research Corporation, a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound.
Thrasos Therapeutics announced that it has completed a $35 Million (U.S.) financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).
› Verified 3 days ago
Kamrin Carver, LMFT, CSAT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 484 S Sunset Ridge Dr, North Salt Lake, UT 84054 Phone: 801-710-0780 | |
Debra Ann Gilmore, LMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 705 Mont Clair Dr, North Salt Lake, UT 84054 Phone: 801-809-4770 | |
Joshua Mcbride, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 940 N 400 E Ste 114, North Salt Lake, UT 84054 Phone: 801-872-9768 |